Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted adjuvant osimertinib with or without chemotherapy after complete resection of EGFR-mutant non-small cell lung cancer
ACTRN12623000552684Phase 2Recruiting
- Sponsor
- The University of Sydney
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by The University of Sydney. Primary endpoint: Disease-free survival at 3 years. Started Sep 2023; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12623000552684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000552684.